Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $16.52 and last traded at $16.48, with a volume of 12,782,316 shares. The stock had previously closed at $17.01.

A number of brokerages have recently issued reports on TEVA. Credit Suisse Group set a $39.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price target on the stock in a research report on Monday, July 24th. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BidaskClub downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Three analysts have rated the stock with a sell rating, twenty have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries Limited presently has an average rating of “Hold” and a consensus target price of $36.14.

The stock has a 50 day moving average of $27.00 and a 200-day moving average of $30.81. The stock’s market cap is $16.81 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the business earned $1.25 EPS. The firm’s revenue was up 12.9% on a year-over-year basis. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be given a $0.085 dividend. The ex-dividend date is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 2.00%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -14.22%.

A number of institutional investors have recently made changes to their positions in the stock. Capital Research Global Investors raised its position in shares of Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after buying an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after buying an additional 6,685,844 shares in the last quarter. FMR LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after buying an additional 6,115,853 shares in the last quarter. Northern Cross LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after buying an additional 2,184,172 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Teva Pharmaceutical Industries Limited by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock worth $428,033,000 after buying an additional 311,894 shares in the last quarter. Hedge funds and other institutional investors own 56.04% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/23/teva-pharmaceutical-industries-limited-teva-reaches-new-12-month-low-at-16-52.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.